Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04444622 · ClinicalTrials.gov registry record · Phase 2
Immunotherapy for Third Line Metastatic Colorectal Cancer
A Phase 2 study of Metastatic Colorectal Cancer, sponsored by Mirror Biologics.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
- 4
- Study locations
NCT04444622: Completed Phase 2 study of Metastatic Colorectal Cancer, sponsored by Mirror Biologics.
NCT04444622 is a Phase 2 study of Metastatic Colorectal Cancer that has completed, run by Mirror Biologics. The registered enrollment target is 29 participants, below the 185-participant average among 45 other Metastatic Colorectal Cancer trials with a reported enrollment target (84% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04444622, a Phase 2 study of Metastatic Colorectal Cancer, has completed, sponsored by Mirror Biologics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a Phase IIB multi-site, open label study of a next generation immunotherapy for third-line MSI-S metastatic colorectal cancer using an "off-the-shelf", non-genetically manipulated living immune cell product (AlloStim) derived from the blood of healthy donors.
Primary Outcome
measurement of the survival on experimental treatment
Conditions Studied
Interventions
- BIOLOGICAL AlloStim
Study Locations (4)
Florida
- Mt. Sinai Comprehensive Cancer Center - Miami Beach
Michigan
- Karmanos Cancer Institute - Detroit
New Jersey
- Summit Health - Florham Park
New York
- Hirschfield Oncology Center - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2021-07-12 |
| Est. Completion | 2025-03-31 |
| Phase | Phase 2 |
What the finished NCT04444622 record still lists
NCT04444622 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 185-participant average among 45 other Metastatic Colorectal Cancer trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Metastatic Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which AlloStim is the first listed.
NCT04444622 reports a single indexed study location in Florida, Michigan, New Jersey.
Frequently Asked Questions
What is clinical trial NCT04444622 about?
NCT04444622 is a clinical study titled "Immunotherapy for Third Line Metastatic Colorectal Cancer". This is a Phase IIB multi-site, open label study of a next generation immunotherapy for third-line MSI-S metastatic colorectal cancer using an "off-the-shelf", non-genetically manipulated living immune cell product (AlloStim) derived from the blood of healthy donors.
What is the current status of trial NCT04444622?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2021-07-12. Estimated completion is 2025-03-31.
What conditions does trial NCT04444622 study?
This clinical trial studies the following conditions: Metastatic Colorectal Cancer.
What interventions are being tested in trial NCT04444622?
The interventions under investigation include: AlloStim (BIOLOGICAL).
Who is sponsoring clinical trial NCT04444622?
This trial is sponsored by Mirror Biologics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04444622 being conducted?
This trial has 4 study locations across Florida, Michigan, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04444622's enrollment target sits among peer trials
29 35th of 45 higher than 10 of 45 other Metastatic Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
RECRUITING · Phase 2
-
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
RECRUITING · Phase 2
-
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
RECRUITING · Phase 2
-
Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC
RECRUITING · Phase 2
-
Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer
RECRUITING · Phase 2
-
Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI